Q4 2025 Stereotaxis Inc Earnings Call Transcript
Key Points
- Stereotaxis Inc (STXS) achieved regulatory approvals in the US and Europe for GenesisX Robot, MAGiC Ablation Catheter, and MAGiC Sweep high-density mapping catheter, marking significant technological progress.
- The company reported a 36% increase in fourth-quarter revenue compared to the prior year, driven by system and catheter sales.
- Stereotaxis Inc (STXS) is transitioning to a more attractive commercial model with a blend of sales, leases, and placements funded by disposable commitments, enhancing revenue potential.
- The company is expanding its product portfolio and market reach, with plans to launch MAGiC with Pulse Field Ablation in Europe by year-end.
- Stereotaxis Inc (STXS) is investing in digital surgery suite technology, with expected FDA clearance for Synchrony and projected revenue of over $3 million from initial demand this year.
- The commercial contribution from new products was modest in 2025, with only one GenesisX system sold and limited revenue from MAGiC and MAGiC Sweep.
- Manufacturing challenges, particularly with the MAGiC catheter, have constrained revenue growth, with production not meeting demand.
- Recurring revenue gross margins were impacted by acquisition-related accounting and lower initial margins on newly launched devices.
- Operating expenses remain high, with significant noncash charges affecting financial results.
- The company faces challenges in transitioning from its previous product ecosystem, with difficulties in switching from third-party catheters to its proprietary MAGiC catheter.
Good afternoon. Thank you for joining us for Stereotaxis' fourth quarter and full year 2025 earnings conference call.
Certain statements during the conference call and questions and answers period to follow may relate to future events, expectations and as such, constitute forward-looking statements within the meaning of Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the company and the future to be materially different from the statements that the company's executives may make today. These risks are described in detail in our public filings with the Securities and Exchange Commission, including our latest period report on Form 10-K or 10-Q. We assume no duty to update these statements.
(Operator Instructions) As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to your host, David Fischel, Chairman and CEO of Stereotaxis. Thank you.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
